Sprint Bioscience Valuation
Is SPRINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of SPRINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPRINT?
Other financial metrics that can be useful for relative valuation.
| What is SPRINT's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | kr93.98m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | -50.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SPRINT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.9x | ||
ALZ Alzinova | 3.9x | -52.0% | kr77.9m |
SPAGO Spago Nanomedical | 13.6x | 43.5% | kr80.4m |
ABERA Abera Bioscience | 27.5x | 10.3% | kr72.8m |
COMBI CombiGene | 10.7x | n/a | kr75.2m |
SPRINT Sprint Bioscience | 1.8x | 33.7% | kr90.6m |
Price to Earnings Ratio vs Industry
How does SPRINT's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is SPRINT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.8x |
| Fair PS Ratio | 4.1x |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?